The role of secondary surgery in recurrent ovarian cancer

International Journal of Surgical Oncology

Volumn 2012, Issue , 2012, Pages

  Lorusso, D ^a   Mancini, M ^a   Di Rocco, R ^a   Fontanelli, R ^a   Raspagliesi, F ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866183391     PISSN: 20901402     EISSN: 20901410     Source Type: Journal    
DOI: 10.1155/2012/613980     Document Type: Review

References (41)

1. Heintz A. P. M., Odicino F., Maisonneuve P., Beller U., Benedet J. L., Creasman W. T., Ngan H. Y. S., Pecorelli S., Carcinoma of the ovary. International Journal of Gynecology and Obstetrics 2003 83 1, supplement 135 166 2-s2.0-2342603957 (Pubitemid 39658498)
2. Sharp F., Blackett A. D., Leake R. E., Berek J. S., Conclusions and recommendations from the Helene Harris Memorial Trust Fifth Biennial International Forum on Ovarian Cancer, May 47, 1995, Glasgow, UK. International Journal of Gynecological Cancer 1995 5 6 449 458 2-s2.0-0028811575 10.1046/j.1525-1438.1995.05060449.x
3. Berek J. S., Tropé C., Vergote I., Surgery during chemotherapy and at relapse of ovarian cancer. Annals of Oncology 1999 10 1, supplement S3 S7 2-s2.0-0032909438 (Pubitemid 29173060)
4. Rustin G. J. S., Van Der Burg M. E. L., Griffin C. L., Guthrie D., Lamont A., Jayson G. C., Kristensen G., Mediola C., Coens C., Qian W., Parmar M. K. B., Swart A. M., Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. The Lancet 2010 376 9747 1155 1163 2-s2.0-77957684487 10.1016/S0140-6736(10)61268-8
5. Tanner E. J., Chi D. S., Eisenhauer E. L., Diaz-Montes T. P., Santillan A., Bristow R. E., Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias? Gynecologic Oncology 2010 117 2 336 340 2-s2.0-77950187418 10.1016/j.ygyno.2010.01.014
6. Morris M., Gershenson D. M., Wharton J. T., Secondary cytoreductive surgery in epithelial ovarian cancer: nonresponders to first-line therapy. Gynecologic Oncology 1989 33 1 1 5 2-s2.0-0024589938 (Pubitemid 19106614)
7. Janicke F., Holscher M., Kuhn W., Von Hugo R., Pache L., Siewert J. R., Graeff H., Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer 1992 70 8 2129 2136 10.1002/1097-0142(19921015) 70:82129::AID-CNCR2820700820>3.0.CO;2-U
8. Segna R. A., Dottino P. R., Mandeli J. P., Konsker K., Cohen C. J., Secondary cytoreduction for ovarian cancer following cisplatin therapy. Journal of Clinical Oncology 1993 11 3 434 439 2-s2.0-0027513786 (Pubitemid 23071038)
9. Pecorelli S., Sartori E., Santin A., Follow-up after primary therapy: management of the symptomatic patient- surgery. Gynecologic Oncology 1994 55 3 S138 S142 2-s2.0-0028625798 10.1006/gyno.1994.1353
10. Vaccarello L., Rubin S. C., Vlamis V., Wong G., Jones W. B., Lewis J. L., Hoskins W. J., Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. Gynecologic Oncology 1995 57 1 61 65 2-s2.0-0028927793 10.1006/gyno.1995.1099
11. Cormio G., Di Vagno G., Cazzolla A., Bettocchi S., Di Gesu' G., Loverro G., Selvaggi L., Surgical treatment of recurrent ovarian cancer: report of 21 cases and a review of the literature. European Journal of Obstetrics Gynecology and Reproductive Biology 1999 86 2 185 188 2-s2.0-0032779618 10.1016/S0301-2115(99)00067-6 (Pubitemid 29391484)
12. Gadducci A., Iacconi P., Cosio S., Fanucchi A., Cristofani R., Riccardo Genazzani A., Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecologic Oncology 2000 79 3 344 349 2-s2.0-0033670096 10.1006/gyno.2000.5992
13. Eisenkop S. M., Friedman R. L., Spirtos N. M., The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 2000 88 144 153 (Pubitemid 30027690)
14. Munkarah A., Levenback C., Wolf J. K., Bodurka-Bevers D., Tortolero-Luna G., Morris R. T., Gershenson D. M., Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. Gynecologic Oncology 2001 81 2 237 241 2-s2.0-0035020455 10.1006/gyno.2001.6143 (Pubitemid 32424168)
15. Tay E. H., Grant P. T., Gebski V., Hacker N. F., Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstetrics and Gynecology 2002 99 6 1008 1013 2-s2.0-0036270410 10.1016/S0029-7844(02)01977-4 (Pubitemid 34621223)
16. Zang R. Y., Li Z. T., Tang J., Cheng X., Cai S. M., Zhang Z. Y., Teng N. N., Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer 2004 100 6 1152 1161 2-s2.0-1542344369 10.1002/cncr.20106 (Pubitemid 38325942)
17. Onda T., Yoshikawa H., Yasugi T., Yamada M., Matsumoto K., Taketani Y., Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. British Journal of Cancer 2005 92 6 1026 1032 2-s2.0-17444426347 10.1038/sj.bjc.6602466 (Pubitemid 40546664)
18. Güngör M., Ortaç F., Arvas M., Kösebay D., Sönmezer M., Köse K., The role of secondary cytoreductive surgery for recurrent ovarian cancer. Gynecologic Oncology 2005 97 1 74 79 2-s2.0-15544367206 10.1016/j.ygyno.2004.11.057 (Pubitemid 40403677)
19. Pfisterer J., Harter P., Canzler U., Richter B., Jackisch C., Hahmann M., Hasenburg A., Burges A., Loibl S., Gropp M., Huober J., Fink D., Du Bois A., The role of surgery in recurrent ovarian cancer. International Journal of Gynecological Cancer 2005 15 6, supplement 3 195 198 10.1111/j.1525-1438.2005. 00430.x (Pubitemid 43096581)
20. Ayhan A., Gultekin M., Taskiran C., Aksan G., Celik N. Y., Dursun P., Salman M. C., Yuce K., Kucukali T., The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience. American Journal of Obstetrics and Gynecology 2006 194 1 49 56 2-s2.0-29544448985 10.1016/j.ajog.2005.06.048 (Pubitemid 43017774)
21. Berek J. S., Hacker N. F., Lagasse L. D., Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstetrics and Gynecology 1983 61 2 189 193 2-s2.0-0020574567 (Pubitemid 13110698)
22. Michel G., Zarca D., Castaigne D., Prade M., Secondary cytoreductive surgery in ovarian cancer. European Journal of Surgical Oncology 1989 15 3 201 204 2-s2.0-0024400436 (Pubitemid 19190110)
23. Goldie J. H., Coldman A. J., A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treatment Reports 1979 63 11-12 1727 1733 2-s2.0-0018569942 (Pubitemid 10138923)
24. Harter P., Bois A. D., Hahmann M., Hasenburg A., Burges A., Loibl S., Gropp M., Huober J., Fink D., Schröder W., Muenstedt K., Schmalfeldt B., Emons G., Pfisterer J., Wollschlaeger K., Meerpohl H. G., Breitbach G. P., Tanner B., Sehouli J., Surgery in recurrent ovarian cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Annals of Surgical Oncology 2006 13 12 1702 1710 2-s2.0-33845657404 10.1245/s10434-006-9058-0 (Pubitemid 44951480)
25. Harter P., Sehouli J., Reuss A., Predictive factors for resection in recurrent ovarian cancer. Intergroup of AGO Kommission Ovar, Ago-OVAR, AGO Austria, MITO and NOGGO. Proceedings of the 12th Biennal Meeting International Gynecologic Cancer Society October 2008 Bangkok, Thailand abstract 38
26. Lenhard S. M., Burges A., Johnson T. R. C., Kirschenhofer A., Bruns C., Linke R., Friese K., Predictive value of PET-CT imaging versus AGO-scoring in patients planned for cytoreductive surgery in recurrent ovarian cancer. European Journal of Obstetrics Gynecology and Reproductive Biology 2008 140 2 263 268 2-s2.0-52949086797 10.1016/j.ejogrb.2008.05.006
27. Benedetti Panici P., De Vivo A., Bellati F., Manci N., Perniola G., Basile S., Muzii L., Angioli R., Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Annals of Surgical Oncology 2007 14 3 1136 1142 2-s2.0-34250223484
28. Harter P., Hahmann M., Lueck H. J., Poelcher M., Wimberger P., Ortmann O., Canzler U., Richter B., Wagner U., Hasenburg A., Burges A., Loibl S., Meier W., Huober J., Fink D., Schroeder W., Muenstedt K., Schmalfeldt B., Emons G., Du Bois A., Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP i trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Annals of Surgical Oncology 2009 16 5 1324 1330 2-s2.0-64249083211 10.1245/s10434-009-0357-0
29. Parmar M. K., Ledermann J. A., Colombo N., Paclitaxel plus platinum- based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. The Lancet 2003 361 2099 2106
30. Pfisterer J., Plante M., Vergote I., Du Bois A., Hirte H., Lacave A. J., Wagner U., Stähle A., Stuart G., Kimmig R., Olbricht S., Le T., Emerich J., Kuhn W., Bentley J., Jackisch C., Lück H. J., Rochon J., Zimmermann A. H., Eisenhauer E., Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. Journal of Clinical Oncology 2006 24 29 4699 4707 2-s2.0-33750588670 10.1200/JCO.2006.06.0913 (Pubitemid 46630933)
31. Marth C., Alexandre J., Hancker L. C., Pegylated liposomal doxorubicin and carboplatin (C-PLD) versus paclitaxel and carboplatin (C-P) in platinum sensitive ovarian cancer (OC) patients (pts): treatment at recurrence and overall survival (OS) final analysis from CALYPSO phase III GCIG trial. Journal of Clinical Oncology 2011 29, supplement, abstr 5052
32. Harter P., Du Bois A., The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence. Current Opinion in Oncology 2005 17 5 505 514 2-s2.0-24044456731 10.1097/01.cco.0000174166.06734.c7 (Pubitemid 41224935)
33. Bristow R. E., Puri I., Chi D. S., Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecologic Oncology 2009 112 1 265 274 2-s2.0-57649083923 10.1016/j.ygyno.2008.08.033
34. Galaal K., Naik R., Bristow R. E., Patel A., Bryant A., Dickinson H. O., Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2010 6 CD007822 2-s2.0-77954986199
35. Wenzel L., Huang H. Q., Monk B. J., Rose P. G., Cella D., Mackey D., Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. Journal of Clinical Oncology 2005 23 24 5605 5612 2-s2.0-24944574020 10.1200/JCO.2005.08.147
36. Yan T. D., Welch L., Black D., Sugarbaker P. H., A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Annals of Oncology 2007 18 5 827 834 2-s2.0-34447311107 10.1093/annonc/mdl428 (Pubitemid 47054078)
37. Yan T. D., Black D., Savady R., Sugarbaker P. H., A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Annals of Surgical Oncology 2007 14 2 484 492 2-s2.0-33846643079 10.1245/s10434-006-9182-x (Pubitemid 46175292)
38. Yan T. D., Black D., Savady R., Sugarbaker P. H., Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. Journal of Clinical Oncology 2006 24 24 4011 4019 2-s2.0-33748460503 10.1200/JCO.2006.07.1142 (Pubitemid 46630752)
39. Chua T. C., Yan T. D., Saxena A., Morris D. L., Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Annals of Surgery 2009 249 6 900 907 2-s2.0-67649201885 10.1097/SLA.0b013e3181a45d86
40. Verwaal V. J., Van Ruth S., De Bree E., Van Slooten G. W., Van Tinteren H., Boot H., Zoetmulder F. A. N., Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. Journal of Clinical Oncology 2003 21 20 3737 3743 2-s2.0-0142087625 10.1200/JCO.2003.04.187 (Pubitemid 46606227)
41. Pomel C., Ferron G., Lorimier G., Rey A., Lhomme C., Classe J. M., Bereder J. M., Quenet F., Meeus P., Marchal F., Morice P., Elias D., Hyperthermic intra-peritoneal chemotherapy using Oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study. European Journal of Surgical Oncology 2010 36 6 589 593 2-s2.0-77953120029 10.1016/j.ejso.2010.04.005